190 related articles for article (PubMed ID: 3085695)
1. [The anti-tumor efficacy of lymphokine-activated killer (LAK) cells induced in vitro from peripheral blood lymphocytes of patients with malignant glioma].
Shimizu K; Miyao Y; Okamoto Y; Matsui Y; Ushio Y; Tsuda N; Hayakawa T; Ishida N; Mogami H
No To Shinkei; 1986 Mar; 38(3):265-71. PubMed ID: 3085695
[TBL] [Abstract][Full Text] [Related]
2. [Clinical studies of adoptive immunotherapy of human disseminated brain tumors with LAK cells and recombinant interleukin-2].
Okamoto Y; Shimizu K; Miyao Y; Yamada M; Ushio Y; Matsui Y; Hayakawa T; Tago H; Ikeda H
No To Shinkei; 1986 Jun; 38(6):593-8. PubMed ID: 3488068
[TBL] [Abstract][Full Text] [Related]
3. [The in vitro antitumor effectiveness of murine lymphokine-activated killer (LAK) cells induced by recombinant IL-2].
Okamoto Y; Shimizu K; Miyao Y; Ushio Y; Matsui Y; Hayakawa T; Tsuda N; Mogami H
No To Shinkei; 1986 Mar; 38(3):233-7. PubMed ID: 3486667
[TBL] [Abstract][Full Text] [Related]
4. [Observations on the local administration of autologous lymphokine activated killer cells and recombinant interleukin-2 in patients with malignant gliomas].
Yoshida S; Takai N; Ono K; Saito T; Tanaka R
No To Shinkei; 1988 Feb; 40(2):119-25. PubMed ID: 3259433
[TBL] [Abstract][Full Text] [Related]
5. [Induction of cytotoxicity from human lymphocytes coated with bispecific antibody against human glioma cells].
Nitta T; Ishizawa A; Ito M; Sato K; Yagita H; Kumura K
No Shinkei Geka; 1990 Nov; 18(11):1001-6. PubMed ID: 2247192
[TBL] [Abstract][Full Text] [Related]
6. Adoptive immunotherapy of a rat glioma using lymphokine-activated killer cells and interleukin 2.
Tzeng JJ; Barth RF; Clendenon NR; Gordon WA
Cancer Res; 1990 Jul; 50(14):4338-43. PubMed ID: 2364388
[TBL] [Abstract][Full Text] [Related]
7. [The antitumor efficacy of lymphokine-activated killer (LAK) cells and gamma interferon production induced in vitro from peripheral blood lymphocytes of patients with malignant gliomas].
Shimizu K; Miyao Y; Okamoto Y; Matsui Y; Ushio Y; Hayakawa T; Tsuda N; Mogami H; Nanjo M; Ishida N
Nihon Gan Chiryo Gakkai Shi; 1986 May; 21(4):760-6. PubMed ID: 3093611
[No Abstract] [Full Text] [Related]
8. [Experimental studies on the treatment of recurrent gliomas].
Yamada M; Shimizu K; Okamoto Y; Miyao Y; Matsui Y; Tsuda N; Mogami H
Gan To Kagaku Ryoho; 1987 Jun; 14(6 Pt 1):1890-5. PubMed ID: 3496051
[TBL] [Abstract][Full Text] [Related]
9. [Analysis of cytolytic activity and cell surface phenotypes of lymphokine activated killer cells stimulated with R-IL 2 and an anti-CD 3 antibody].
Kikuchi T; Sakai H; Nakamura N; Watanabe M; Ohno T
No To Shinkei; 1990 Jun; 42(6):575-80. PubMed ID: 2119634
[TBL] [Abstract][Full Text] [Related]
10. Interleukin-2 or autologous lymphokine-activated killer cell treatment of malignant glioma: phase I trial.
Jacobs SK; Wilson DJ; Kornblith PL; Grimm EA
Cancer Res; 1986 Apr; 46(4 Pt 2):2101-4. PubMed ID: 3512079
[TBL] [Abstract][Full Text] [Related]
11. [Effects of phenytoin on cell-mediated immunity].
Okamoto Y; Shimizu K; Tamura K; Miyao Y; Yamada M; Matsui Y; Tsuda N; Mogami H
No To Shinkei; 1987 Oct; 39(10):931-6. PubMed ID: 3501727
[TBL] [Abstract][Full Text] [Related]
12. Circulating cytokines in patients with metastatic cancer treated with recombinant interleukin 2 and lymphokine-activated killer cells.
Gemlo BT; Palladino MA; Jaffe HS; Espevik TP; Rayner AA
Cancer Res; 1988 Oct; 48(20):5864-7. PubMed ID: 3139285
[TBL] [Abstract][Full Text] [Related]
13. Analysis of the murine lymphokine-activated killer (LAK) cell phenomenon: dissection of effectors and progenitors into NK- and T-like cells.
Kalland T; Belfrage H; Bhiladvala P; Hedlund G
J Immunol; 1987 Jun; 138(11):3640-5. PubMed ID: 3495566
[TBL] [Abstract][Full Text] [Related]
14. Antitumor efficacy of lymphokine-activated killer cells and recombinant interleukin-2 in vivo: survival benefit and mechanisms of tumor escape in mice undergoing immunotherapy.
Mulé JJ; Ettinghausen SE; Spiess PJ; Shu S; Rosenberg SA
Cancer Res; 1986 Feb; 46(2):676-83. PubMed ID: 3484431
[TBL] [Abstract][Full Text] [Related]
15. Assessment of human natural killer and lymphokine-activated killer cell cytotoxicity against Toxoplasma gondii trophozoites and brain cysts.
Dannemann BR; Morris VA; Araujo FG; Remington JS
J Immunol; 1989 Oct; 143(8):2684-91. PubMed ID: 2477453
[TBL] [Abstract][Full Text] [Related]
16. [Induction of LAK cells and CTL in patients with brain tumor and research of its clinical application].
Moriki A
Nihon Geka Hokan; 1989 Jan; 58(1):107-18. PubMed ID: 2802908
[TBL] [Abstract][Full Text] [Related]
17. Identification and selection of human lymphokine activated killer cell effectors and novel recycling intermediates by unique light-scattering properties.
Loudon WG; Abraham SR; Owen-Schaub LB; Hemingway LL; Hemstreet GP; DeBault LE
Cancer Res; 1988 Apr; 48(8):2184-92. PubMed ID: 3258186
[TBL] [Abstract][Full Text] [Related]
18. Lymphokine-activated killer cells in rats: analysis of tissue and strain distribution, ontogeny, and target specificity.
Vujanovic NL; Herberman RB; Hiserodt JC
Cancer Res; 1988 Feb; 48(4):878-83. PubMed ID: 3257411
[TBL] [Abstract][Full Text] [Related]
19. Cytolytic activity of natural killer cells and lymphokine activated killer cells against hepatitis A virus infected fibroblasts.
Baba M; Hasegawa H; Nakayabu M; Fukai K; Suzuki S
J Clin Lab Immunol; 1993; 40(2):47-60. PubMed ID: 7932628
[TBL] [Abstract][Full Text] [Related]
20. [Low susceptibility of choriocarcinoma cell lines to lymphokine activated killer (LAK) cells].
Kameda T; Negoro T; Hagiwara M; Koyama M; Matsuzaki N; Saji F; Tanizawa O
Nihon Sanka Fujinka Gakkai Zasshi; 1989 Jan; 41(1):1-6. PubMed ID: 2784473
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]